Despite the proportion of tumors harboring EGFR, ALK, or KRAS alterations being consistent with the frequency reported in lung adenocarcinoma, the reduced subgroup size, especially for ALK-positive cases, might have limited the strength of the models. This evidence concerns the gene ALK and lung adenocarcinoma.